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with generalized estimating equations were used to estimate the
odds of being persistent for each LMD class relative to statins
while controlling for patient, plan, and prescription characteris-
tics. RESULTS: The overall proportion of patients persistent to
therapy in the 1 year after therapy initiation was 11% for BAS
(N = 9853), 25% for ER niacin (N = 9404), 32% for ﬁbrates (N
= 21,004), 39% for statins (N = 105,178), and 44% for eze-
timibe (N = 974). The proportion of patients who were persis-
tent with ER niacin therapy declined from 44% to 30%, 27%,
and 24% over the ﬁrst four quarters after therapy initiation. Sim-
ilarly, mean PDC for niacin was 68% in Q1, 43% in Q2, 36%
in Q3, and 32% in Q4 of the 1 year after therapy initiation.
Excepting ezetimibe, multivariate analyses conﬁrmed signiﬁ-
cantly lower odds of persistence on all LMD classes relative to
statins (p < 0.001). CONCLUSION: Excepting BAS, we found
that ER niacin had the lowest persistence among all LMD
classes. Since long-term treatment is generally necessary in
persons with dyslipidemia, suboptimal persistence may affect the
overall success of LMD therapy.
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DOES 90-DAY PRESCRIPTION SUPPLY AT RETAIL IMPROVE
COMPLIANCE IN A MANAGED CARE SETTING?
Thiebaud P, Patel BV
Medimpact Healthcare Systems, Inc, San Diego, CA, USA
OBJECTIVE: To evaluate the effect of a new program that
allowed patients to ﬁll 90-day prescriptions in retail pharmacies.
METHODS: The research is a case-control natural experiment.
A total of 38,852 patients in the treatment cohort received drug
beneﬁt through a managed care organization that initiated a 
90-day supply retail option in January 1, 2005. Patients were
evaluated if they used agents to treat diabetes, dyslipidemia, or
hypertension and were continuously eligible for beneﬁt for 18
months—9 months pre- and post-January 1, 2005. The control
cohort comprised 49,738 patients who were insured in the same
managed care organization, and used the same drugs and were
followed for the same length of time the year before and after
January 1, 2004. Treatment and control patients were matched
on a number of dimensions—including demographic character-
istics, copays, and baseline drug consumption—using the
weighted sum of absolute case-control differences. The effect of
the new 90-day retail program was then evaluated with the
matched sample using the difference-in-differences estimator.
Two outcomes were evaluated: the number of prescription in the
above therapeutic classes and the duration of supply. RESULTS:
The introduction of 90-day dispensing at retail allowed patients
to reduce the number of prescription they ﬁlled by an average of
1.2 for diabetes, 2.2 for antilipidemics, and 4.0 for antihyper-
tensives. Despite this reduction, actual total drug supply
increased as the average length of supply per prescription
increased. Total supply increased by 4.3 days for antihyperten-
sives, 11.5 days for antilipidemics, and by 75.3 days for diabetes.
CONCLUSION: Reactions to the introduction of a new retail
dispensing option demonstrate that dispensing ﬂexibility is valu-
able to the patients and can lead to improvement in compliance,
presumably because reﬁlling a prescription every 30 days can be
burdensome.
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ADHERENCE TO EVIDENCE-BASED STATIN GUIDELINES
REDUCES RISK FOR ACUTE MYOCARDIAL INFARCTION
WITH AT LEAST 50%.
Penning-van Beest FJ1, Goettsch WG2, Klungel OH3, Kastelein JJ4,
Herings RM2
1PHARMO Institute, Utrecht,The Netherlands, 2PHARMO Institute,
Utrecht,The Netherlands, 3Universiteit Utrecht, Utrecht,The
Netherlands, 4Academisch Medisch Centrum, Amsterdam,The
Netherlands
OBJECTIVES: We investigated the “real world” effectiveness of
statin therapy, focusing on the effect of dose and early treatment
discontinuation on the risk for acute myocardial infarction
(AMI). METHODS: Data were obtained from the PHARMO
Record Linkage System including among others linked drug-dis-
pensing records and hospital records for over two million indi-
viduals of the Netherlands. New users of statins in the period
January 1 1991 until December 31 2004, °Y´18 years of age were
included in the study cohort. Exposure to statins, both in terms
of persistence and dose, was determined over the ﬁrst two treat-
ment years. To determine the risk for AMI, patients were fol-
lowed from this two-year time point until the ﬁrst hospital
admission for AMI, death, or end of the study period (Decem-
ber 31, 2004), whichever was earliest. Patients were classiﬁed
into two groups according to their risk of cardiovascular disease
at the start of outcome follow-up. RESULTS: The study cohort
included 46,332 low-risk statin users (78%) and 12,762 high-
risk statin users (22%). 31,557 patients (53%) discontinued
statin use within two years. 20,883 patients (35%) were persis-
tent statin users with an average equipotent dose °Y´4. A 40%
reduction in risk of AMI with two-year persistent statin use was
observed in low- and high-risk users. The protective effect of
statin use increased with a higher equipotent dose; a 25% reduc-
tion in risk of AMI with an average equipotent dose °Ü3 and a
60% risk reduction with an average equipotent dose °Y´4. CON-
CLUSION: The results show that statins are suboptimally dosed
in real life and used too short for having the maximum beneﬁt
in terms of preventing AMI. Our ﬁndings corroborate ﬁndings
from clinical trials insofar that the longer patients are treated 
and the higher the dose, the more successful the prevention of
AMI.
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LONG-TERM CARDIOVASCULAR OUTCOMES OF
COMPLIANCE AND PERSISTENCE WITH HYPERTENSION
THERAPY
Halpern MT1, Vincze G2, Stewart WF3, Khan ZM4
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OBJECTIVES: While managed care data can be used to assess
medication compliance and persistence, these databases gener-
ally do not permit observation of long-term outcomes. We there-
fore applied modeling techniques to explore the impacts of
compliance and persistence with hypertension therapy on long-
term cardiovascular outcomes among managed care hyperten-
sion patients. METHODS: We analyzed 12-month blood
pressure (BP) and compliance/persistence using data for hyper-
tension patients receiving valsartan therapy from the Geisinger
Clinic, a U.S. regional healthcare network. Long-term cardio-
vascular outcomes (myocardial infarction, stroke, coronary
artery bypass, angioplasty, and cardiovascular death) were based
on algorithms from the Physicians’ Health Study (13 years
follow-up) and Women’s Health Study (7 years) as presented by
Glynn et al. (2002). No signiﬁcant differences were observed
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between the compliant/persistent and non-compliant/non-persis-
tent groups for other cardiovascular risk factors (age, diabetes,
smoking status, cholesterol, and alcohol). RESULTS: Compliant
patients (those with medication-possession ratios >80%) had 12-
month average systolic and diastolic BP values 3.5mmHg (p <
0.0005) and 0.5mmHg (non-signiﬁcant) lower, respectively, than
those of non-compliant patients. Assuming these differences
remain over time, the Glynn algorithms predict a 4.6% decrease
(95% conﬁdence interval 2.4%, 6.9%) in the relative risk of
adverse cardiovascular outcomes for men and a 16.3% decrease
(95% CI 12.2%, 20.6%) for women. Persistent patients (those
remaining on valsartan therapy for 12 months) had ﬁnal systolic
and diastolic BP values 4.1mmHg and 2.5mmHg (both p < 0.05)
lower than those for non-persistent patients, projecting an 8.4%
decrease (95% CI 3.1%, 13.9%) in relative risk of adverse car-
diovascular outcomes for men and a 26.6% decrease (95% CI
19.8%, 33.9%) for women. CONCLUSIONS: Compliance with
and persistence to hypertension therapy predicted substantial
decreases in adverse cardiovascular outcomes. These impacts
may also lead to improved patient-reported outcomes and
decreased costs, and can be used to assess long-term treatment
cost-effectiveness.
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IMPACT OF ADHERENCE TO ANTIHYPERLIPIDEMIC DRUGS
ON TOTAL PHARMACY AND MEDICAL COSTS
El Khoury AC, Shaya FT, Samant ND
University of Maryland, Baltimore, MD, USA
OBJECTIVE: To determine the impact of adherence to antihy-
perlipidemic drug therapy on patients’ total pharmacy and
medical costs, from the payer’s perspective. METHODS: Retro-
spective database analysis of Maryland Medicaid medical and
pharmacy claims for the period January 1, 2001–December 31,
2003. Inclusion criteria: Continuously enrolled patients older
than 18 years who had at least one prescription claim for any of
the statins. Exclusion criteria (to obtain incident cohort): Patients
who had at least a claim before July 1st, 2002. Non-adherence
was deﬁned as a failure to reﬁll a prescription claim. General-
ized linear models with a logarithmic link function were used to
determine the impact of adherence to statins on medical costs,
after adjusting for age, gender, race and comorbidities by con-
structing a Charlson Comorbidity Index. RESULTS: Total of
2746 patients, 34% male, 44% African-Americans, and 65%
older than 63. Patients who adhere to their antihyperlipidemic
pharmacotherapy incur 26.08% (p < 0.0001; CI -0.41, -0.19)
and 33.25% (p = 0.0002; CI -0.62, -0.19) lower total costs
(pharmacy and medical) and medical costs respectively than
those who do not. Those between the age of 40 and 63 and those
who are African-American incur 19.22% (p < 0.0001; CI -0.31,
0.11) and 14.05% (p = 0.002; CI -0.25, -0.05) lower total costs
than those who are older than 63 and those who are Caucasian
respectively. A unit increase in the comorbidity index leads to a
10.13% (p < 0.0001; CI 0.07, 0.12) increase in total costs. CON-
CLUSIONS: On average, adherence to antihyperlipidemic phar-
macotherapy results in lower total costs. More awareness given
to adherence patterns on statins could lower the payers’ total
medical costs.
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DETERMINANTS OF ADHERENCE TO STATINS IN A
MEDICAID MANAGED CARE POPULATION
Samant ND, Shaya FT, El Khoury AC
University of Maryland, Baltimore, MD, USA
OBJECTIVE: To identify the determinants of drug adherence
among statin users in a Medicaid managed care population.
METHODS: Retrospective database analysis of Maryland 
Medicaid medical and pharmacy claims for the period January
1, 2001–December 31, 2003. Inclusion criteria: Continuously
enrolled patients older than 18 years who had at least one pre-
scription claim for any of the statins. Exclusion criteria (to obtain
incident cohort): Patients who had at least a claim before July
1st, 2002. Non-adherence was deﬁned as a failure to reﬁll a pre-
scription claim. Logistic regression models were built to deter-
mine the association of age, gender, race, and comorbidities
(based on Charlson Comorbidity Index) with drug adherence.
RESULTS: Out of 1997 patients, 61% females, 57% African
Americans, and 70% 60 years old or younger. Caucasians were
more adherent than African Americans (30% vs. 22%), younger
patients less adherent than older patients (24% vs. 26%) and
females less adherent than males (22% vs. 28%). In the logistic
multivariate model, adjusting for demographics and comorbidi-
ties, African Americans (OR 0.68, 95% CI 0.549, 0.841), and
males (OR 1.33, 95% CI 1.083, 1.641) were signiﬁcantly more
likely to adhere to statin therapy. CONCLUSION: In this Med-
icaid population, adherence to statin pharmacotherapy is lower
among females and African Americans. The effectiveness of
adherence programs may be improved if they are earmarked to
these speciﬁc subpopulations.
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UNDERSTANDING PATIENT BELIEFS TO DESIGN
MEDICATION ADHERENCE MESSAGING
Foley K1, Hansen LG2
1Thomson Medstat, Philadelphia, PA, USA, 2Thomson Medstat,
Northwood, NH, USA
OBJECTIVE: To identify patient segments based on beliefs about
medications, reasons for non-adherence, and demographics to
inform actionable adherence improvement messaging.
METHODS: A total of 5630 patients self-identifying as having
high cholesterol responded to the Thomson Medstat PULSE con-
sumer health behavior survey in October–November 2005.
These respondents received cholesterol-speciﬁc questions about
their adherence, beliefs and reasons for non-adherence. Beliefs
about the necessity of and concerns about taking cholesterol-
lowering medications were assessed via ﬁve likert-scale ques-
tions, each with summed scores ranging between 5 and 25. A
cut-point of 15 was used to identify high versus low necessity 
or concern creating four patient segments: high necessity/
high concern (HNHC), low necessity/high concern (LNHC), low
necessity/low concern (LNLC), high necessity/low concern
(HNLC). Non-adherence was measured as skipping, taking
smaller doses, delaying, and/or stopping medication ﬁlls in the
past 30 days. Reasons for non-adherence included: cost, forget-
ting, experience with the medication, self-assessed need, and 
convenience. RESULTS: A total of 4737 respondents reported
taking prescription cholesterol-lowering medications with
28.1% reporting non-adherence. Non-adherence rates varied sig-
niﬁcantly among patient segments: 51.6% of LNHC respon-
dents, 36.1% of HNHC, 29.1% of LNLC and 20.8% of HNLC
were non-adherent (chi-square p < 0.0001). Type of and reasons
for non-adherence also varied. Patients with high concerns were
more likely to report taking smaller doses (33.5% of HNHC and
36.5% of LNHC versus 22.4% of LNLC and 20.6% of HNLC)
than those with low concerns and they were more likely to be
non-adherent due to experiences with medications (26.6% of
HNHC and 30.2% of LNHC versus 12.2% LNLC and 8.7% of
HNLC). Patient segments also differed by income (chi-square p
< 0.0001), education (chi-square p < 0.0001), and health status
(chi-square p < 0.0001). CONCLUSION: Creating psycho-
graphic patient segments using patient beliefs about medication
